A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00486668
Recruitment Status : Unknown
Verified June 2016 by NSABP Foundation Inc.
Recruitment status was:  Active, not recruiting
First Posted : June 15, 2007
Last Update Posted : June 6, 2016
Information provided by (Responsible Party):
NSABP Foundation Inc